Loading stock data…
Danaher Corporation (DHR)
$193.78-2.41 (-1.23%)
Market OpenUpdated 11:04 AM EDT
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Danaher Corporation in the Healthcare sector is trading at $193.78 with a market capitalization of $121.7B. Wall Street consensus targets $242.35 (23 analysts), implying a +25.1% move over the next 12 months. The stock is currently 20% below its 52-week high of $242.80, remaining 4.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +25.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.95B↓ | $6.84B↑ | $6.05B↑ | $5.94B↑ | $5.74B |
| Gross Profit | $3.59B↓ | $3.97B↑ | $3.52B | $3.52B↑ | $3.51B |
| Operating Income | $1.34B↓ | $1.50B↑ | $1.15B↑ | $760.00M↓ | $1.27B |
| Net Income | $1.03B↓ | $1.20B↑ | $908.00M↑ | $555.00M↓ | $954.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$121.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.70%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.97%
Volume
Today's trading volume
627,763
Recent News
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation
Danaher Corporation (NYSE:DHR) is one of the best long term stocks to buy according to hedge funds. On June 10, Danaher completed its acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now function as a standalone operating company within Danaher’s Diagnostics segment, retaining its original brand identity while […]
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported […]
Just How Far Could Corning Stock Swing From Here?
If you hold shares in the specialty glass and ceramics maker, you are already carrying exposure to a remarkably wide range of potential outcomes priced by the options market.
3 Mid-Cap Stocks Walking a Fine Line
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Danaher (DHR) Stock Is Up, What You Need To Know
Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 2.8% in the morning session after its recently acquired subsidiary, Masimo, received U.S. Food and Drug Administration (FDA) clearance for an artificial intelligence-enabled feature on its wearable patient monitoring platform.